A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma by Wang, Qiu et al.
 
A Small-Molecule Probe of the Histone Methyltransferase G9a
Induces Cellular Senescence in Pancreatic Adenocarcinoma
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Yuan, Yuan, Qiu Wang, Joshiawa Lanair James Paulk, Stefan
Kubicek, Melissa M. Kemp, Drew J. Adams, Alykhan Farid Shamji,
Bridget K. Wagner, and Stuart L. Schreiber. 2012. A small-
molecule probe of the histone methyltransferase g9a induces
cellular senescence in pancreatic adenocarcinoma. ACS Chemical
Biology 7(7): 1152-1157.
Published Version doi:10.1021/cb300139y
Accessed February 19, 2015 10:46:58 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11210614
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAA Small-Molecule Probe of the Histone Methyltransferase G9a





†,# Melissa M. Kemp,
† Drew J. Adams,
†
Alykhan F. Shamji,*
,† Bridget K. Wagner,*
,† and Stuart L. Schreiber*
,†,‡,§,∥
†Chemical Biology Program and
∥Howard Hughes Medical Institute, Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts
02142, United States
‡Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
§Chemical Biology Training Program, Harvard University, Boston, Massachusetts 02115, United States
* S Supporting Information
ABSTRACT: Post-translational modiﬁcations of histones alter
chromatin structure and play key roles in gene expression and
speciﬁcation of cell states. Small molecules that target
chromatin-modifying enzymes selectively are useful as probes
and have promise as therapeutics, although very few are
currently available. G9a (also named euchromatin histone
methyltransferase 2 (EHMT2)) catalyzes methylation of lysine
9 on histone H3 (H3K9), a modiﬁcation linked to aberrant
silencing of tumor-suppressor genes, among others. Here, we
report the discovery of a novel histone methyltransferase
inhibitor, BRD4770. This compound reduced cellular levels of
di- and trimethylated H3K9 without inducing apoptosis, induced senescence, and inhibited both anchorage-dependent and
-independent proliferation in the pancreatic cancer cell line PANC-1. ATM-pathway activation, caused by either genetic or small-
molecule inhibition of G9a, may mediate BRD4770-induced cell senescence. BRD4770 may be a useful tool to study G9a and its
role in senescence and cancer cell biology.
H
istone methyltransferases (HMTs) and demethylases
(HDMs) dynamically alter the methylation state of
histone proteins. Somatic mutation and ampliﬁcation of HMTs
are frequently observed in human cancers, and at least 22 out of
50 arginine and lysine HMTs encoded in the human genome
have been associated with cancer or other diseases in humans
or mice.
1 Methylation of lysine 9 on histone H3 (H3K9) is
associated with transcriptional silencing, and this mark is often
found in the promoter regions of aberrantly silenced tumor-
suppressor genes in cancer cells.
2 Euchromatin histone
methyltransferase 1 (EHMT1), also known as GLP or
KMT1D, forms a heteromeric complex with G9a (also called
EHMT2 or KMT1C) to yield H3K9 methyltransferase activity
in euchromatin.
3 Knockdown of G9a signiﬁcantly reduces di-
and trimethylation of H3K9 in cell culture and in mice.
4,5
Few selective small-molecule inhibitors of chromatin-
modifying enzymes exist. Current methyltransferase inhibitors
fall into two categories: H3 peptide substrate-competitive
inhibitors and S-adenosylmethionine (SAM) cofactor-compet-
itive inhibitors (Figure 1a). The substrate-competitive com-
pound BIX-01294 was identiﬁed as a selective G9a inhibitor by
high-throughput screening.
6 Despite its relative selectivity, BIX-
01294 shows toxicity apparently not linked to its HMT
inhibitory activity. A structural analogue, UNC0638, was
recently reported to have increased potency and reduced cell
toxicity.
7 Cofactor-competitive inhibitors include BIX-01338,
discovered in the same screen as BIX-01294, and the natural
product chaetocin.
8 Both compounds are non-selective, with
similar IC50 values against G9a and the HMT SUV39H1. BIX-
01338 neither modulates cellular H3K9 methylation status nor
inhibits cancer cell growth.
6 Inspired by the isoform selectivity
exhibited by certain inhibitors of kinases and histone
deacetylases (Figure 1a), we were interested in developing
new SAM-competitive inhibitors selective toward subsets of
HMTs or even a single HMT. Such compounds should be
useful tools for the study of methyltransferases.
Here, we describe the discovery of BRD4770, a SAM
mimetic and analogue of BIX-01338 that selectively inhibits a
subset of HMTs, including G9a, in biochemical assays and in
cells. Similar to knockdown of G9a,
4,9,10 BRD4770 induced a
senescent phenotype in a pancreatic cancer cell line. BRD4770
also inhibited both anchorage-dependent and -independent cell
proliferation and induced G2/M cell-cycle arrest. The protein
kinases ataxia telangiectasia mutated (ATM) and ataxia
telangiectasia and Rad3-related protein (ATR) are thought to
be important in DNA damage-induced senescence.
11 We show
that BRD4770 activates the ATM pathway without inducing
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BRD4770 is a novel probe for studying G9a and its role in
cellular senescence.
Although an S-adenosylmethionine (SAM)-competitive
inhibitor of G9a, BIX-01338, has been reported, it inhibits
several methyltransferases, including SUV39H1, and lacks
cellular activity.
6 To improve selectivity and achieve G9a
inhibition in cells, we synthesized a focused library of 117 2-
substituted benzimidazoles as potential SAM mimetics (Figure
1b). These compounds were tested for biochemical inhibition
of G9a; 41 showed >45% inhibition at 50 μM (Supporting
Figure S1a). Knockdown of G9a resulted in an enlarged and
ﬂattened cell morphology, and visual examination revealed that
eight compounds induced similar morphological changes. We
also measured cellular ATP levels, as a surrogate of cell viability,
in HeLa cells treated with this compound collection. After a 2-
day treatment, 17 compounds decreased ATP levels in a dose-
dependent manner (Supporting Figure S1a). Overall, ﬁve
compounds were active in all three assays (Supporting Figure
S1b). We focused on BRD4770, which induced the strongest
morphological change in cells, and BRD9539, the potential
active form of BRD4770 in cells (Figure 1c).
We next examined the biochemical activity of BRD9539
against ﬁve methyltransferases: G9a, SUV39H1, PRC2, NSD2,
and DNMT1. BRD9539 inhibited G9a activity in a dose-
dependent manner, with an IC50 of 6.3 μM (Figure 1d). The
inhibitory eﬀect of BRD9539 decreased with increasing SAM
concentrations (Supporting Figure S2), but detailed kinetic
analysis is required to determine whether BRD9539, like its
analogue BIX-01338, is SAM-competitive. Existing SAM-
competitive inhibitors, such as BIX-01338 and chaetocin,
inhibit G9a but also inhibit SUV39H1.
8,12 BRD9539 also
inhibited PRC2 activity with a similar IC50. No inhibition of
SUV39H1 and DNMT1 was observed up to 40 μM. Partial
inhibition of NSD2 was observed only at 40 μM. BRD9539 is a
more potent biochemical inhibitor than its methyl-ester
analogue BRD4770, with 20% remaining G9a activity compared
to 45% of BRD4770 at screening concentration. However,
BRD9539 had no activity in cell-based assays, presumably due
to impaired cell permeability compared to that of BRD4770.
We assume that BRD4770 is converted to BRD9539 in cells
since methyl esters of biologically active carboxylic acids are
rapidly hydrolyzed in cells and often used as cell-active “pro-
drugs” of the less cell-permeable carboxylic acids. In addition,
the activities of 16 other chromatin-modifying enzymes and 100
kinases involved in cell-cycle regulation and cancer cell biology
were tested for activity in the presence of 5 or 10 μM
BRD9539; no activity was seen in any of these assays
(Supporting Table S1 and S2).
To evaluate BRD4770 activity in cells, we analyzed the
methylation state at various histone lysines by mass
spectrometry. A signiﬁcant decrease in di- and trimethylation
levels of H3K9, along with an increase in monomethylation
level, was observed after 24-h treatment with 10 μM BRD4770.
In comparison, BIX-01294, a substrate-competitive inhibitor of
G9a, also decreased H3K9 di- and trimethylation, but with an
increase of unmodiﬁed H3K9, possibly due to a diﬀerent
mechanism of action (Figure 2a). Methylation at other
positions, such as H3K27 and H3K36, appeared unaﬀected.
We also assessed H3K9 methylation by Western blot.
Treatment of 5 μM BRD4770 for 24 h decreased H3K9
trimethylation level by 23% in PANC-1 cells (Figure 2b).
Although we observed a slight decrease in H3K36 trimethy-
lation, the trimethylation levels at other positions, such as
H3K4, H3K27, and H3K79, remained largely unchanged
(Figure 2b). The EC50 of BRD4770 in PANC-1 cells,
determined by Western blotting for trimethylated H3K9, was
approximately 5 μM (Figure 2c), which was signiﬁcantly higher
compared to existing substrate-competitive inhibitors (Support-
ing Figure S3). These data are consistent with inhibition of G9a
in cells following BRD4770 treatment. While our biochemical
experiments suggested that BRD9539 also inhibits PRC2
activity, we have not observed evidence of PRC2 inhibition
in cells with BRD4770 in our experiments to date.
The selective substrate-competitive inhibitor BIX-01294
inhibits GLP and G9a
6 but is toxic to cells, which may be
caused by oﬀ-target eﬀects in cells. Thus, we sought to
determine whether BRD4770 induced apoptosis by measuring
caspase-3/7 activity. Even after 72 h treatment, BRD4770 did
not increase caspase activity in PANC-1 cells at any
concentration (Figure 2d). In contrast, BIX-01294 strongly
induced caspase activity after only 24 h (Figure 2e). UNC0638,
an analogue of BIX-01294 with improved potency and lower
cell toxicity, also induced caspase activity after 72 h, but only at
a much higher concentration compared to its cellular EC50
(Figure 2f). Thus, the apoptotic eﬀect appears to be unrelated
to G9a inhibition. These results suggest that BRD4770 may be
Figure 1. Small-molecule inhibitors of G9a. (A) Classiﬁcation of
existing histone methyltransferases inhibitors (HMTi). Representative
substrate- and cofactor-competitive HMTi’s are shown. (B) Synthetic
chemistry scheme yielding 117 benzimidazoles as potential SAM
mimetics for competitive inhibition of HMTs. (C) Chemical structures
of BRD4770 and BRD9539. (D) Biochemical activities of G9a, PRC2,
SUV39H1, NSD2, and DNMT1 following treatment with indicated
concentrations of BRD9539. Data represent the mean and standard
error of four independent reactions.
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at its eﬀective concentration.
Knockdown of G9a inhibits cell growth and induces cellular
senescence in PC3 prostate cancer cells.
4 To assess the eﬀects
of inhibiting G9a in pancreatic cancer cells, we compared
knockdown of G9a (Supporting Figure S4) to treatment with
BRD4770 in PANC-1 cells. Both genetic and small-molecule
inhibition of G9a resulted in enlarged and ﬂattened cell
morphology, with increased senescence-associated β-galactosi-
dase staining (Figure 3a). Anchorage-dependent and -in-
dependent cell growth were monitored in PANC-1 cells by
nuclear staining and growth in soft agarose, respectively.
BRD4770 treatment reduced the number of cells after 72 h
(Figure 3b). Compound-treated cells showed reduced histone
H3 phosphorylation at serine 10 (Supporting Figure S5),
suggesting reduced proliferation. Colony formation in soft
agarose was also signiﬁcantly reduced following BRD4770
treatment (Figure 3c,d). Using ﬂuorescence-activated cell
sorting, we found that treatment with BRD4770 increased
the cell population in G2/M and decreased the fraction of G0/
G1 cells (Figure 3e).
These data led us to wonder whether the compound induces
cell-cycle arrest. ATM and ATR are important regulators of
cell-cycle arrest caused by DNA damage, including senes-
cence.
13,14 To investigate the mechanism further underlying
cell-growth inhibition induced by BRD4770, we examined the
eﬀect of BRD4770 treatment on ATM and ATR pathway
activation. Since ATM and ATR are regulated by autophos-
phorylation, we assessed their phosphorylation levels by
immunoﬂuorescent staining. Treatment with BRD4770 led to
increases in phosphorylated ATM and nuclear translocation of
phosphorylated ATM in PANC-1 cells (Figure 4a). We did not
observe similar changes in ATR (Figure 4b). Consistent with
activation of ATM but not ATR, BRD4770 treatment increased
phosphorylation of Chk2 and decreased cdc25C levels
(downstream targets of the ATM pathway) but did not
increase phosphorylation of Chk1 (a downstream target of
ATR) (Figure 4c). Knockdown of G9a, and to a lesser extent
GLP, yielded similar results (Figure 4d).
Although ATM pathway activation is usually linked to DNA
damage, especially that caused by double-stranded breaks, it can
also be induced in the absence of DNA damage.
15,16 To
determine whether BRD4770 causes ATM activation by
inducing DNA damage, we stained for phospho-H2AX, which
is rapidly phosphorylated and localized to sites of DNA damage
in response to double-stranded breaks.
17 No increase in
phospho-H2AX staining was observed by ﬂow cytometry or
by ﬂuorescence microscopy (Supporting Figure S6a). Similarly,
no increase in DNA damage was observed in individual cells
following BRD4770 treatment by comet assay, measuring the
tail moment length (Supporting Figure S6b). Our data suggest
BRD4770 causes ATM activation in the absence of DNA
damage.
Changes in chromatin structure have been implicated in
ATM activation and cellular senescence, but the precise
mechanism remains uncharacterized.
18 For example, treatment
with HDAC inhibitors can trigger cellular senescence by
inducing ATM phosphorylation.
18−20 Here we show that
treatment with an HMT inhibitor causes similar phenotypes.
It is unclear if changing histone methylation is suﬃcient to
induce ATM pathway activation and senescence, or whether
additional changes in chromatin structure, such as telomere
Figure 2. Cellular eﬀects of BRD4770 on histone methylation. (A) Mass-spectrometric analysis of methylation levels of histone H3 lysines 9, 27, and
36 in cells treated with DMSO (black bars), 10 μM BRD4770 (gray bars), or 10 μM BIX-01294 (white bars) for 24 h. (B) Western blot analysis of
trimethylation levels of histone H3 lysines 4, 9, 27, 36, and 79 in PANC-1 cells after 24-h treatment with the indicated concentrations of BRD4770.
Tubulin was used as an internal loading control. (C) Western blot analysis of relative trimethylation levels of histone H3 lysine 9 in PANC-1 cells
after 24-h treatment with the indicated concentrations of BRD4770. Data represent the mean and standard error of four independent replicates.
Caspase-3/7 activity in PANC-1 cells was measured after 24 h (dashed line) or 72 h (solid line) treatment with (D) BRD4770, (E) BIX-01294, or
(F) UNC0638. Results were normalized by cellular ATP levels, and data represent the mean and standard error of six independent replicates.
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induced by BRD4770 as a secondary eﬀect and contribute to
the overall phenotype. For example, BRD4770 also induces
increased levels of lysine acetylation in cells (Supporting Figure
S7) without inhibiting histone deacetylases (Supporting Table
S1).
Cellular senescence may result from a variety of stresses,
mainly mediated by two tumor-suppressor pathways involving
p53 and p16-pRB.
11,21 However, the senescent phenotype
resulting from genetic or chemical inhibition of G9a in PANC-1
cells may be independent of these two pathways. PANC-1, a
human pancreatic ductal carcinoma cell line that resists
apoptotic cell death, harbors four of the most common
mutations in pancreatic cancer, including homozygous deletion
of CDKN2A (which encodes p16), and alterations in TP53
(deletion of one allele and mutation at codon 273 within the
DNA-binding domain of the other allele).
22 BRD4770 activates
the ATM pathway and induces senescence in this genetic
context. Overall, our data suggest that BRD4770 is a novel
small-molecule probe of G9a activity and its role in senescence
of cancer cells.
■ METHODS
Cell Culture and Compound Treatment. PANC-1 and HeLa
cells (ATCC) were cultured in DMEM medium containing 10% (v/v)
FBS and 100 U mL−1 penicillin-streptomycin. BRD4770, BRD9539,
BRD2502, BRD9398, BRD1490, and BI-37 were synthesized in our
lab. Chemical characterization of BRD4770 and BRD9539 is included
in Supporting Information. BIX-01294, UNC0638, and chaetocin were
purchased from Sigma-Aldrich.
Enzymatic Assays. Biochemical activity of G9a was measured as
described.
6 Biochemical assays for SUV39H1 and DNMT1 activity
were from BPS Bioscience. Chaetocin was used as a positive control in
G9a and SUV39H1 assays. PRC2 and NSD2 activity were measured
using dissociation-enhanced lanthanide ﬂuorescent immunoassay
(DELFIA) in white 384-well streptavidin-coated plates (PerkinElmer).
For detailed assay procedure please see Supporting Information.
Mass-Spectrometric Analysis of Histone Methylation. HeLa
cells were seeded in 10 cm dishes and treated with BRD4770 or
DMSO for 24 h. Histones were extracted according to the
manufacturer’s protocol (Abcam). Histone bands were isolated from
SDS-PAGE gel and treated with double propionylation and trypsin.
Samples were analyzed on an Orbitrap mass spectrometer as
described.
6
Gene Silencing. Small-interfering RNAs against GLP (s36392)
and G9a (s21469, s21470) were obtained from Applied Biosystems.
siRNAs (25 nM) were transfected into PANC-1 cells using
Lipofectamine 2000 (Invitrogen), with medium changed 24 h later.
Transfected cells were cultured for 72 h, and RNA and protein were
collected for real-time PCR and Western blot analysis, respectively.
Western Blotting. Cells were lysed in RIPA buﬀer (20 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1%
(w/v) NP-40, 1% (w/v) sodium deoxycholate, 2.5 mM sodium
Figure 3. Comparison of genetic and small-molecule inhibition of G9a in PANC-1 cells. (A) Senescence-associated β-galactosidase expression in
PANC-1 cells following knockdown of G9a with two independent siRNA constructs or treatment with BRD4770 for 5 days. Scale bars = 50 μm. (B)
Nuclear count in PANC-1 cells treated for 72 h with BRD4770, ﬁxed, and stained with Hoechst dye. Total nuclei per well were counted by
automated microscopy (see Methods). Data represent the mean and standard error of 16 independent replicates. * indicates p < 0.003, ** indicates
p < 0.001 (t test). (C) Brightﬁeld images of PANC-1 cells after 3-day treatment with BRD4770, followed by 10-day culture in soft agarose. Scale bar
=5 0μm. (D) Quantiﬁcation of PANC-1 cell growth in soft agarose by DNA measurement (see Methods). * indicates p < 0.001 (t test). (E)
Evaluation of cell cycle in PANC-1 cells treated for 3 days with DMSO (left panel) or BRD4770 (right panel). Inset, calculated percentage of cells in
each phase.
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leupeptin, protease inhibitor and phosphatase inhibitor). Total protein
was separated by 4−12% SDS-PAGE and transferred to a PVDF
membrane (iBlot system, Invitrogen). Blots were developed using
chemiluminescence detection (SuperSignal, Thermo Fisher Scientiﬁc
Image Station 4000MM Pro, Kodak). Images were quantiﬁed using
ImageJ image analysis software. Antibody concentrations are included
as Supporting Information.
Immunoﬂuorescence and Microscopy. PANC-1 cells were
seeded in black optical 96-well plates and treated with compounds for
72 h. Cells were ﬁxed using 4% (v/v) paraformaldehyde for 20 min,
permeabilized for 20 min with 0.1% (v/v) Triton X-100, blocked with
PBS containing 2% (w/v) BSA at 4 °C overnight, and incubated at 4
°C overnight with either p-ATM (S1981) mouse mAb (10H11.E12,
Cell Signaling) or p-ATR (S428) rabbit Ab (Cell Signaling) at 1:250
dilution. Cy3-labeled secondary antibodies (Jackson ImmunoRe-
search) were added with Hoechst 33342 (Invitrogen) and observed
with an Axiovert 200 M ﬂuorescence microscope (Zeiss) at 400X
magniﬁcation. Cell number analysis was performed on an ImageXpress
Micro automated microscope (Molecular Devices) using a 4X
objective with laser-based focusing. Image analysis was performed
using the Cell Count module in the MetaXpress software application
(Molecular Devices).
Senescence Analysis. PANC-1 cells were seeded in 12-well
plates, treated with compounds and siRNAs, and stained with
Senescence β-Galactosidase Staining Kit (Cell Signaling), with
detection of blue color by light microscopy.
Anchorage-Independent Soft Agarose Assay. PANC-1 cells
were seeded and treated with BRD4770 in 6-well plates for 72 h. Cells
were trypsinized and tested for soft agar colony formation using
CytoSelect 96-Well Cell Transformation Assay (Cell Biolabs), using
the CyQuant GR dye to measure total cellular nucleic acid levels.
Fluorescence was detected with an Analyst HT plate reader (LJL
Biosystems) using a 485/520 nm ﬁlter set.
Flow Cytometry. Treated cells were washed in PBS, ﬁxed in ice-
cold 70% (v/v) ethanol for 30 min at 4 °C, followed by two washes
with PBS. Next, 100 μgm L −1 RNase was added and incubated at 37
°C for 15 min, 50 μgm L −1 propidium iodide was added, and cell cycle
was analyzed with a BD LSR II ﬂow cytometer (BD Biosciences).
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